Related Experiment Videos
Hepatitis B virus-associated membraneous nephropathy: clinical features, immunological profiles and outcome
1Department of Medical Research, Veterans General Hospital, Taipei, Taiwan.
Abstract:
To evaluate the clinical features, immunological profiles and the prognosis of hepatitis B virus-associated membraneous nephropathy (HBVMN), 34 patients (25 boys and 9 girls) were studied from April 1981 to November 1987. With Fab fragments of monoclonal antibodies, hepatitis B e antigen (HBeAg) was detected in the glomerular deposits from 30 cases (88.2%) and in the sera from 32 cases (94.1%). These results suggest that HBeAg plays an important role in the development of HBVMN. In addition, clinical trials of 32 cases demonstrate a relatively poor response to the steroid therapy with persistent heavy proteinuria (32.4%) or a high frequent relapse rate (38.2%); only 1 case (3.1%) had early response. In 4 cases follow-up renal biopsy was performed, progressive sclerosis with interstitial fibrosis being noted in each instance. The stage of membraneous nephropathy examined under the light microscope, had progressed from stage I or II to stage III. One had impaired renal function. Therefore, HBVMN does not always take a benign course. In the immunological profiles, significant hypocomplementemia with low C3, C4 and properdin factor B levels were found during the initial 6 months after the onset of disease. Hepatitis B surface antigen (HBsAg) circulating immune complexes (CIC) were also significantly higher. However, the levels of HBsAg CIC did not correlate with the degree of proteinuria or hematuria. In patients with persistent HBaAg carriage, serum HBeAg status alone did not correlate with remission rate, and remission occurred usually before the HBeAg seroconversion to anti-HBe. These results suggest that factors other than HBeAg play important roles in HBVMN.
Insights
Hepatitis B virus-associated membranous nephropathy (HBVMN) often shows poor response to steroids and can progress, indicating it
Area of Science:
- Nephrology
- Immunology
- Hepatology
Background:
- Hepatitis B virus-associated membranous nephropathy (HBVMN) is a significant cause of kidney disease.
- Understanding the clinical features, immunological profiles, and prognosis of HBVMN is crucial for patient management.
Purpose of the Study:
- To evaluate the clinical features, immunological profiles, and prognosis of 34 patients with HBVMN.
- To determine the role of hepatitis B e antigen (HBeAg) in the pathogenesis of HBVMN.
Main Methods:
- Analysis of clinical data, immunological markers, and renal biopsy findings in 34 HBVMN patients.
- Detection of HBeAg in glomerular deposits and sera using Fab fragments of monoclonal antibodies.
- Assessment of response to steroid therapy and follow-up renal biopsies.
Main Results:
- HBeAg was detected in 88.2% of glomerular deposits and 94.1% of sera, suggesting its role in HBVMN development.
- Poor response to steroid therapy (32.4% persistent proteinuria, 38.2% relapse) and disease progression (sclerosis, fibrosis) were observed.
- Hypocomplementemia and elevated hepatitis B surface antigen (HBsAg) circulating immune complexes (CIC) were noted, but HBsAg CIC levels did not correlate with proteinuria or hematuria.
Conclusions:
- HBVMN may not follow a benign course, with significant rates of poor treatment response and disease progression.
- While HBeAg is frequently detected, factors beyond HBeAg appear to influence HBVMN pathogenesis and remission.
- Further research is needed to elucidate the complex factors contributing to HBVMN outcomes.